Login to Your Account



Clinic Roundup


Wednesday, August 31, 2011
Pearl Therapeutics Inc., of Redwood City, Calif., reported data from a Phase IIb study of formoterol fumarate metered dose inhaler (FF MDI; PT005), a long-acting beta-2 agonist, compared to placebo and Foradil Aerolizer (Novartis AG) in patients with moderate to severe chronic obstructive pulmonary disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription